+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab"

India Anti-rheumatic Drug Market Forecasts from 2023 to 2028 - Product Thumbnail Image

India Anti-rheumatic Drug Market Forecasts from 2023 to 2028

  • Report
  • October 2023
  • 75 Pages
  • India
From
From
Canada Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027 - Product Thumbnail Image

Canada Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027

  • Report
  • September 2022
  • 77 Pages
  • Canada
From
From
From
Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry - Product Thumbnail Image

Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry

  • Newsletter
  • August 2026
  • 2 Pages
  • Global
From
From
From
US Axial Spondyloarthritis Market outlook to 2028 - Product Thumbnail Image

US Axial Spondyloarthritis Market outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
From
From
From
Loading Indicator

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms. Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients. Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more